AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_04_08_2024_03_19_11_791897.jpg)
_04_08_2024_03_17_14_221652.webp)
Highlights
-
IMU’s CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx to showcased at the American Association for Cancer Research (AACR) Annual Meeting.
-
The oncolytic virus CF33-hNIS (VAXINIA), either alone or combined with KEYTRUDA®, offers a safe treatment alternative for patients with advanced cancer.
-
Positive outcomes from VAXINIA treatment have justified expanding the patient cohorts for biliary tract cancer and other tumour types.
-
In contrast to chemotherapy alone, administering HER-Vaxx through vaccination has demonstrated a 40% improvement in overall survival.
Imugene Limited (ASX: IMU) is set to present its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting, in San Diego, California. The poster presentations are scheduled for 9 April 2024.
The poster presentation will highlight that VAXINIA alone or in combination with KEYTRUDA® provides a safe treatment alternative for advanced cancer patients. Encouraging results in one patient with biliary tract cancer after treatment with VAXINIA warrant cohort expansions in biliary tract cancer and other types of tumours.
The poster presentation for HER-Vaxx will showcase that vaccination with HER-Vaxx resulted in a 40% overall survival benefit compared to chemotherapy alone. Moreover, HER-Vaxx induced HER2-specific antibody levels are associated with a reduction in tumours.
IMU shares traded at AU$0.102 apiece at the time of writing on 8 April 2024.